{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Karmali R"],"funding":["NCI NIH HHS"],"pagination":["43"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11947441"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["15(1)"],"pubmed_abstract":["Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this poor prognostic impact. In this multicenter retrospective study, we sought to confirm this observation by evaluating survival outcomes among patients with relapsed/refractory DHL and DEL treated with CART and evaluate outcomes of relapse post-CART. A total of 408 adult patients with relapsed/refractory DLBCL from 13 academic centers were included based on the availability of DHL and DEL. All 408 patients were included in the DHL (n = 80) vs non-DHL (n = 328) analysis, while 333 patients were included in the analysis of DHL (n = 80) vs DEL (n = 74) vs non (n = 179). On MVA, there were no differences for PFS for DHL vs non-DHL (HR 0.8, 95%CI 0.5-1.3, p = 0.35) or DHL vs DEL "],"journal":["Blood cancer journal"],"pubmed_title":["Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy."],"pmcid":["PMC11947441"],"funding_grant_id":["P30 CA008748"],"pubmed_authors":["Ollila T","Ma S","Danilov AV","Shouse G","Cohen JB","Torka P","Karmali R","Bhansali R","Roy I","Epperla N","Zurko J","Romancik J","Fitzgerald L","David K","Shah NN","Kenkre VP","Stephens DM","Gordon LI","Tabiti B","Pro B","Winter J","Barta SK","Moreira J","Moyo TK","Hess B"],"additional_accession":[]},"is_claimable":false,"name":"Double hit & double expressor lymphomas: a multicenter analysis of survival outcomes with CD19-directed CAR T-cell therapy.","description":"Double-hit (DHL) and double expressor (DEL) DLBCL have poor prognosis with standard therapy but CART may overcome this poor prognostic impact. In this multicenter retrospective study, we sought to confirm this observation by evaluating survival outcomes among patients with relapsed/refractory DHL and DEL treated with CART and evaluate outcomes of relapse post-CART. A total of 408 adult patients with relapsed/refractory DLBCL from 13 academic centers were included based on the availability of DHL and DEL. All 408 patients were included in the DHL (n = 80) vs non-DHL (n = 328) analysis, while 333 patients were included in the analysis of DHL (n = 80) vs DEL (n = 74) vs non (n = 179). On MVA, there were no differences for PFS for DHL vs non-DHL (HR 0.8, 95%CI 0.5-1.3, p = 0.35) or DHL vs DEL ","dates":{"release":"2025-01-01T00:00:00Z","publication":"2025 Mar","modification":"2026-06-06T16:46:15.255Z","creation":"2025-07-13T03:04:50.344Z"},"accession":"S-EPMC11947441","cross_references":{"pubmed":["40140360"],"doi":["10.1038/s41408-025-01250-8"]}}